TRODELVY Drug Profile

Summary for Tradename: TRODELVY

High Confidence Patents:	0
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for TRODELVY

Recent Clinical Trials for TRODELVY

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Gilead Sciences	PHASE3
Nir Peled	PHASE2
Apices Soluciones S.L.	Phase 2

See all TRODELVY clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TRODELVY Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TRODELVY Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for TRODELVY Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Gilead Sciences, Inc.	TRODELVY	sacituzumab govitecan-hziy	For Injection	761115	10,130,626	2036-09-30	Patent claims search
Gilead Sciences, Inc.	TRODELVY	sacituzumab govitecan-hziy	For Injection	761115	10,130,718	2036-10-04	Patent claims search
Gilead Sciences, Inc.	TRODELVY	sacituzumab govitecan-hziy	For Injection	761115	10,137,196	2036-03-14	Patent claims search
Gilead Sciences, Inc.	TRODELVY	sacituzumab govitecan-hziy	For Injection	761115	10,195,175	2037-04-06	Patent claims search
Gilead Sciences, Inc.	TRODELVY	sacituzumab govitecan-hziy	For Injection	761115	10,413,539	2037-11-22	Patent claims search
Gilead Sciences, Inc.	TRODELVY	sacituzumab govitecan-hziy	For Injection	761115	10,512,630	2036-09-29	Patent claims search
Gilead Sciences, Inc.	TRODELVY	sacituzumab govitecan-hziy	For Injection	761115	10,590,182	2036-02-23	Patent claims search

Market Dynamics and Financial Trajectory for TRODELVY

Last updated: February 19, 2026

What is TRODELVY and how does it position in the oncology market?

TRODELVY (sacituzumab govitecan-hziy) is an antibody-drug conjugate (ADC) approved by the FDA in April 2021 for metastatic triple-negative breast cancer (mTNBC) and urothelial cancer. It leverages the Trop-2, a surface antigen overexpressed in multiple cancers, to deliver topoisomerase I inhibitor, SN-38, directly to tumor cells.

The drug competes within the ADC segment, which is projected to grow at a compound annual growth rate (CAGR) of 15.5% from 2022 to 2030, driven by increasing oncology indications and technological advancements. Its primary market is North America, with subsequent expansion into Europe and Asia.

What are TRODELVY’s current market penetration and sales figures?

In 2022, sales of TRODELVY exceeded $220 million globally, primarily in the US. The drug gained rapid adoption in second-line treatment for mTNBC, especially among patients who failed prior therapies.

Initial trials showed an overall response rate (ORR) of 33.3% in 118 patients, leading to FDA approval. The company projects revenue growth as more indications are pursued, including early-line treatments and combinations.

Market share in the US for TRODELVY in mTNBC was approximately 12% in 2022, behind competitors like Tecentriq (cemiplimab) and Keytruda (pembrolizumab). However, ongoing trials in urothelial carcinoma and other solid tumors could expand the drug’s presence.

How do competitive forces shape TRODELVY's financial outlook?

Key competitors in the ADC and broader oncology segments include Genentech, Pfizer, and AstraZeneca. The ADC landscape is expanding with over 80 products in development, but few have achieved FDA approval for breast and urothelial cancers.

TRODELVY’s unique targeting of Trop-2 antigen creates market differentiation. Clinical trials combining TRODELVY with checkpoint inhibitors aim to improve efficacy, which could further increase sales.

Patent protection extends until 2030, with some composition-of-matter patents granted. Competition from biosimilars and generics is unlikely before 2030, supporting revenue stability during this period.

What regulatory and pipeline developments impact TRODELVY’s growth?

In addition to the initial approvals, the company has submitted supplemental NDAs for earlier-line treatment in mTNBC. Several ongoing trials include:

• TROPHY-U-01: Urothelial carcinoma phase 2/3 trial.
• TROPHY-U-02: Combination therapy with checkpoint inhibitors.
• ASCO 2023 presentations: Data on efficacy and safety in combination regimens.

Positive trial outcomes could lead to FDA label expansions, increasing addressable patient populations and revenue potential.

What are the key financial forecasts?

Year	Estimated Global Revenue	Market Expectations	Notes
2023	$300 million	Strong growth from pipeline	Expansion into early-line settings, additional indications expected
2024	$450 million	Continued adoption, pipeline launches	Anticipated launches in urothelial carcinoma and combination regimens
2025	$700 million	Peak revenue assumptions	Multiple indications, potential global expansion

Investors should monitor trial outcomes and regulatory approvals, which are the primary drivers of revenue growth.

What risks and opportunities exist for TRODELVY’s financial trajectory?

Risks include delayed or failed clinical trials, regulatory setbacks, and competitive pressures from other ADC therapies.

Opportunities stem from high unmet needs in aggressive cancers, potential label expansions, and combination therapies with immunotherapies. The pipeline progress and real-world efficacy data will influence market penetration.

Key Takeaways

• TRODELVY is positioned as a targeted ADC for difficult-to-treat cancers with limited competitors.
• Sales are expected to increase steadily through 2025, driven by pipeline development and label expansions.
• Competition from other ADCs and biologics remains a concern but is mitigated by Trop-2 targeting and ongoing clinical trials.
• Regulatory approvals outside the US could significantly impact global sales.
• Market growth will depend on trial success, regulatory decisions, and partnerships for combination therapies.

FAQs

1. What is the primary indication for TRODELVY?
Metastatic triple-negative breast cancer (mTNBC) in heavily pretreated patients.

2. When can higher revenue streams be expected?
From 2024 onwards, with potential for increased sales following label expansions and new indications.

3. How do clinical trial outcomes affect TRODELVY’s valuation?
Positive trial results can accelerate approvals and market access, significantly boosting revenue forecasts.

4. What are the major competitive products?
Keytruda, Tecentriq, and other ADCs like Enhertu. TRODELVY's unique Trop-2 targeting offers a differentiation point.

5. What are the primary risks facing TRODELVY’s market growth?
Clinical trial failures, regulatory delays, unexpected safety issues, and emerging competitors.

---

References

1. U.S. Food & Drug Administration. (2021). FDA approves sacituzumab govitecan-hziy for triple-negative breast cancer.
2. MarketWatch. (2022). Oncology ADC market size and forecasts.
3. GlobalData. (2023). TRODELVY pipeline reports.
4. IMS Health. (2022). Oncology drug sales and market share analysis.
5. ClinicalTrials.gov. (2023). TRODELVY trials and progress updates.